Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 16/20 | 0.82 |
| ▸ | S1PR5 | Q9H228 | 17/20 | 0.55 |
| ▸ | HTR2A | P28223 | 1/20 | 0.55 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.55 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.55 |
| ▸ | S1PR3 | Q99500 | 4/20 | 0.53 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.50 |
| ▸ | LTK | P29376 | 1/20 | 0.48 |
| ▸ | TAOK1 | Q7L7X3 | 1/20 | 0.48 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9998210 | 0.90 | S1PR1 (1.00) | S1PR1S1PR5HTR2AKCNH2SIGMAR1 | |
| SCHEMBL178072 | 0.82 | S1PR1 (0.84) | S1PR1S1PR5HTR2AKCNH2SIGMAR1 | |
| SCHEMBL3041770 | 0.78 | S1PR5 (0.85) | S1PR1S1PR5HTR2AKCNH2SIGMAR1 | |
| SCHEMBL12038134 | 0.76 | S1PR1 (0.76) | S1PR1S1PR5 | |
| SCHEMBL3031896 | 0.73 | S1PR5 (0.95) | S1PR1S1PR5S1PR3 | |
| SCHEMBL6570369 | 0.73 | S1PR1 (0.71) | S1PR1 | |
| SCHEMBL3038019 | 0.72 | S1PR5 (1.00) | S1PR1S1PR5HTR2AKCNH2SIGMAR1 | |
| SCHEMBL3028338 | 0.71 | S1PR5 (0.81) | S1PR1S1PR5HTR2AKCNH2SIGMAR1 | |
| SCHEMBL3043562 | 0.71 | S1PR5 (1.00) | S1PR1S1PR5S1PR3 | |
| SCHEMBL3039290 | 0.71 | S1PR5 (0.77) | S1PR1S1PR5HTR2AKCNH2SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110318388-A1 | S1P Receptors Modulators and Their Use Thereof | AKAAL PHARMA PTY LTD (AU) | 2011-12-29 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110318388-A1 | S1P Receptors Modulators and Their Use Thereof | S1PR1, S1PR5, S1PR2 | S1PR1 1/4885S1PR5 2/4885HTR2A 736/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.